Stock VIGL VIGIL NEUROSCIENCE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Vigil Neuroscience, Inc.

Equities

VIGL

US92673K1088

Market Closed - Nasdaq
Other stock markets
 02:00:01 07/05/2024 am IST 		5-day change 1st Jan Change
2.89 USD -4.62% Intraday chart for Vigil Neuroscience, Inc. +11.15% -14.50%
17/04 Vigil Neuroscience, Inc. Presents Key Findings from Illuminate & Ignite Studies in ALSP At the 2024 American Academy of Neurology Annual Meeting CI
26/03 Wedbush Trims Vigil Neuroscience Price Target to $22 From $23, Maintains Outperform Rating MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Vigil Neuroscience, Inc. Presents Key Findings from Illuminate & Ignite Studies in ALSP At the 2024 American Academy of Neurology Annual Meeting
Vigil Neuroscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Vigil Neuroscience, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Vigil Neuroscience Names Petra Kaufmann Chief Medical Officer
Vigil Neuroscience, Inc. Announces Executive Changes
Vigil Neuroscience Reports Positive Interm Results for Treatment of Axonal Spheroids and Pigmented Glia
Vigil Neuroscience, Inc. Reports Positive Interim Data from Phase 2 Ignite Proof-Of-Concept Clinical Trial Evaluating Iluzanebart as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE
Vigil Neuroscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Vigil Neuroscience Shares Rise After First Participant Dosed in Phase 1 Trial of Potential Alzheimer's Disease Treatment
Vigil Neuroscience, Inc. Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating Vv-3927, a Small Molecule Trem2 Agonist, for Potential Treatment of Alzheimer's Disease
Vigil Neuroscience, Inc Provides an Update on the Small Molecule TREM2 Agonist, VG-3927
Vigil Says Orphan Drug Designation Application for Proposed Leukoencephalopathy Therapy Secured European Positive Opinion
Vigil Neuroscience, Inc. Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for Vgl101 for the Treatment of ALSP
Vigil Neuroscience's VGL101 Healthy Volunteer Trial Shows Favorable Safety, Tolerability Profile
Vigil Neuroscience, Inc. Presents VGL101 Complete Phase 1 Data and Phase 2 Ignite Trial Design at the 2023 American Neurological Association Annual Meeting
Ververv Neuroscience, Inc. Receives Notification from the U.S. Food and Drug Administration Regarding Its Investigational New Drug Application to Evaluate the Company's Oral Small Molecule Trem2 Agonist Vv-3927
Vigil Neuroscience, Inc. Appoints Christopher J. Silber, M.D. as Chief Medical Officer
Vigil Neuroscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Vigil Neuroscience Names Christopher Silber Chief Medical Officer
Vigil Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VIGL Stock
  4. News Vigil Neuroscience, Inc.
  5. Other languages
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW